Zeo ScientifiX, Inc. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
For Q1 FY2026 (three months ended April 30, 2026), ZEO ScientifiX reported revenues of $2.581M vs. $1.149M prior year (+124.6%, +$1.432M). Six-month revenues reached $4.027M vs. $2.239M (+79.9%, +$1.788M). Net loss improved to ~$1.0M from ~$2.6M; gross margins stable at ~80%. Growth driven by increased allogenic biologic product sales and expanded physician adoption in Florida.
Why this rating
Strong revenue growth and path to profitability material to $7.1M market-cap company; 36% annualized revenue pace suggests real traction, but micro-cap risk and OTC status remain
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.